Therapy Areas: Central Nervous System
Ryne Biotechnology Awarded USD 4m from the California Institute for Regenerative Medicine
16 February 2023 - - The California Institute for Regenerative Medicine has awarded US-based therapeutics company Ryne biotechnology, Inc a USD 4m Clinical Stage Research Program (CLIN1) grant, the company said.

This funding will enable the company to advance its lead candidate RNDP-001, an iPSC-derived dopamine neuron progenitor for the treatment of both inherited and idiopathic forms of Parkinson's disease, through submission of an Investigational New Drug application within the next 12 months.

RNDP-001 has completed preclinical efficacy and safety studies.

This CIRM award will allow Ryne Bio to finalize its IND-package including the production of GMP-grade materials to enable the evaluation of RNDP-001 in Phase 1 clinical trials for both inherited and idiopathic forms of Parkinson's disease.

Beyond RNDP-001, Ryne Bio is developing a platform of drug candidates, including next-generation, gene-modified programs that have the potential to modify and reverse disease progression in Parkinson's disease and other moderate to severe central nervous system disorders.

In addition to funding from CIRM, Ryne Bio was launched and seeded in 2022 by Saisei Ventures, an emerging venture capital firm focused on building revolutionary advanced medicine companies.

Ryne Bio is a biotechnology company pioneering next-generation approaches to cure neurological disorders.

The company utilizes induced pluripotent stem cell technology, a Nobel-winning breakthrough that enables scientists to manufacture any human cell, in order to advance Ryne Bio's off-the-shelf neuron replacement therapeutics.

By focusing on an iPSC technology platform, and forging partnerships with leaders in surgical delivery and clinical development, Ryne Bio is dedicated to advancing a best-in-class pipeline targeting neurological diseases.

At CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and act with a sense of urgency to succeed in that mission.

To meet this challenge, our team of highly trained and experienced professionals actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of TODAY's most promising stem cell technologies.

With USD 5.5bn in funding and more than 150 active stem cell programs in our portfolio, CIRM is the world's largest institution dedicated to helping people by bringing the future of cellular medicine closer to reality.

Saisei Ventures is a leading venture capital firm dedicated to building next-generation companies in the healthcare sector.

It aims to partner with passionate bio-entrepreneurs to develop and implement business strategies that will generate strong proof of concept, clinical validation, and market value.

With operations in Japan and the United States, Saisei aims to enhance the value of its portfolio companies by leveraging its unique networks in and the institutional advantages of both countries.

Saisei's first fund, Saisei Bioventures L.P., is focused on building revolutionary cell and gene therapy and regenerative medicine companies from foundational technologies originating from Japan.
Login
Username:

Password: